Adan, R., van der Beek, E. M., Buitelaar, J. K., Cryan, J. F., Hebebrand, J., Higgs, S., Schellekens, H., & Dickson, S. L. (2019). Nutritional psychiatry: Towards improving mental health by what you eat. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 29(12), 1321–1332. https://doi.org/10.1016/j.euroneuro.2019.10.011

Aerde, K. J., Kalverdijk, L. J., Reimer, A. G., & Widdershoven, J. A. (2008). QT interval prolongation and psychotropic drugs in children and adolescents: Proposed guideline. Nederlands Tijdschrift Voor Geneeskunde, 152, 1765-1770.

Ahmed, R., Borst, J., Wei, Y. C., & Aslani, P. (2017). Parents’ Perspectives About Factors Influencing Adherence to Pharmacotherapy for ADHD. Journal of attention disorders, 21(2), 91–99. https://doi.org/10.1177/1087054713499231

Ahmed, M., Malik, M., Teselink, J., Lanctôt, K. L., & Herrmann, N. (2019). Current Agents in Development for Treating Behavioral and Psychological Symptoms Associated with Dementia. Drugs & aging, 36(7), 589–605. https://doi.org/10.1007/s40266-019-00668-7

Aman, M. G., Marks, R. E., Turbott, S. H., Wilsher, C. P., & Merry, S. N. (1991). Clinical effects of methylphenidate and thioridazine in intellectually subaverage children. Journal of the American Academy of Child and Adolescent Psychiatry, 30(2), 246–256. https://doi.org/10.1097/00004583-199103000-00013

Arnold, L.E.  (2000). Methylphenidate vs. amphetamine: comparative review. Journal of Attention Disorders 3(4), 200-211. https://doi.org/10.1177/108705470000300403

Ban, van den E., Souverein, P., Swaab, H., van Engeland, H., Heerdink, R., & Egberts, T. (2010a). Trends in incidence and characteristics of children, adolescents, and adults initiating immediate- or extended-release methylphenidate or atomoxetine in the Netherlands during 2001-2006. Journal of child and adolescent psychopharmacology, 20(1), 55–61. https://doi.org/10.1089/cap.2008.0153

van den Ban, E., Souverein, P. C., Swaab, H., van Engeland, H., Egberts, T. C., & Heerdink, E. R. (2010b). Less discontinuation of ADHD drug use since the availability of long-acting ADHD medication in children, adolescents and adults under the age of 45 years in the Netherlands. Attention deficit and hyperactivity disorders, 2(4), 213–220. https://doi.org/10.1007/s12402-010-0044-9

Ban, van den E. F., Souverein, P. C., van Engeland, H., Swaab, H., Egberts, T. C., & Heerdink, E. R. (2015). Differences in ADHD medication usage patterns in children and adolescents from different cultural backgrounds in the Netherlands. Social psychiatry and psychiatric epidemiology, 50(7), 1153–1162. https://doi.org/10.1007/s00127-015-1068-4

Banaschewski, T., Coghill, D., Santosh, P., Zuddas, A., Asherson, P., Buitelaar, J., Danckaerts, M., Döpfner, M., Faraone, S. V., Rothenberger, A., Sergeant, J., Steinhausen, H. C., Sonuga-Barke, E. J., & Taylor, E. (2006). Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. European child & adolescent psychiatry, 15(8), 476–495. https://doi.org/10.1007/s00787-006-0549-0

Bangs, M. E., Wietecha, L. A., Wang, S., Buchanan, A. S., & Kelsey, D. K. (2014). Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine. Journal of child and adolescent psychopharmacology, 24(8), 426–434. https://doi.org/10.1089/cap.2014.0005

Barkley, R. A., Fischer, M., Smallish, L., & Fletcher, K. (2003). Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics, 111(1), 97–109. https://doi.org/10.1542/peds.111.1.97

Biederman, J., Melmed, R. D., Patel, A., McBurnett, K., Konow, J., Lyne, A., Scherer, N., & SPD503 Study Group (2008). A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics, 121(1), e73–e84. https://doi.org/10.1542/peds.2006-3695

Biederman, J., Monuteaux, M. C., Spencer, T., Wilens, T. E., & Faraone, S. V. (2009). Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study. Pediatrics, 124(1), 71–78. https://doi.org/10.1542/peds.2008-3347

Biederman, J., Wigal, S. B., Spencer, T. J., McGough, J. J., & Mays, D. A. (2006). A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder. Clinical therapeutics, 28(2), 280–293. https://doi.org/10.1016/j.clinthera.2006.02.008

Biederman, J., Baldessarini, R. J., Wright, V., Knee, D., & Harmatz, J. S. (1989). A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy. Journal of the American Academy of Child and Adolescent Psychiatry, 28(5), 777–784. https://doi.org/10.1097/00004583-198909000-00022

Bloch, M. H., & Mulqueen, J. (2014). Nutritional supplements for the treatment of ADHD. Child and adolescent psychiatric clinics of North America, 23(4), 883–897. https://doi.org/10.1016/j.chc.2014.05.002

Block, S. L., Kelsey, D., Coury, D., Lewis, D., Quintana, H., Sutton, V., Schuh, K., Allen, A. J., & Sumner, C. (2009). Once-daily atomoxetine for treating pediatric attention-deficit/hyperactivity disorder: comparison of morning and evening dosing. Clinical pediatrics, 48(7), 723–733. https://doi.org/10.1177/0009922809335321

Bruera, E., Fainsinger, R., MacEachern, T., & Hanson, J. (1992). The use of methylphenidate in patients with incident cancer pain receiving regular opiates. A preliminary report. Pain, 50(1), 75–77. https://doi.org/10.1016/0304-3959(92)90114-Q

Bruera, E., Miller, M. J., Macmillan, K., & Kuehn, N. (1992). Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain. Pain, 48(2), 163–166. https://doi.org/10.1016/0304-3959(92)90053-E

Catalá-López, F., Hutton, B., Núñez-Beltrán, A., Page, M. J., Ridao, M., Macías Saint-Gerons, D., Catalá, M. A., Tabarés-Seisdedos, R., & Moher, D. (2017). The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials. PloS one, 12(7), e0180355. https://doi.org/10.1371/journal.pone.0180355

Castells, X., Ramon, M., Cunill, R., Olivé, C., & Serrano, D. (2020). Relationship Between Treatment Duration and Efficacy of Pharmacological Treatment for ADHD: A Meta-Analysis and Meta-Regression of 87 Randomized Controlled Clinical Trials. Journal of attention disorders, 1087054720903372. Advance online publication. https://doi.org/10.1177/1087054720903372

Chacko, A., Pelham, W. E., Gnagy, E. M., Greiner, A., Vallano, G., Bukstein, O., & Rancurello, M. (2005). Stimulant medication effects in a summer treatment program among young children with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 44(3), 249–257. https://doi.org/10.1097/00004583-200503000-00009

Charach, A., Yeung, E., Climans, T., & Lillie, E. (2011). Childhood attention-deficit/hyperactivity disorder and future substance use disorders: comparative meta-analyses. Journal of the American Academy of Child and Adolescent Psychiatry, 50(1), 9–21. https://doi.org/10.1016/j.jaac.2010.09.019

Charnsil C. (2011). Efficacy of atomoxetine in children with severe autistic disorders and symptoms of ADHD: an open-label study. Journal of attention disorders, 15(8), 684–689. https://doi.org/10.1177/1087054710376907

Chang, Z., Ghirardi, L., Quinn, P. D., Asherson, P., D’Onofrio, B. M., & Larsson, H. (2019). Risks and Benefits of Attention-Deficit/Hyperactivity Disorder Medication on Behavioral and Neuropsychiatric Outcomes: A Qualitative Review of Pharmacoepidemiology Studies Using Linked Prescription Databases. Biological psychiatry, 86(5), 335–343. https://doi.org/10.1016/j.biopsych.2019.04.009

Cheng, J. Y., Chen, R. Y., Ko, J. S., & Ng, E. M. (2007). Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. Psychopharmacology, 194(2), 197–209. https://doi.org/10.1007/s00213-007-0840-x

Childress, A. C., Findling, R. L., Wu, J., Kollins, S. H., Wang, Y., Martin, P., & Robertson, B. (2020). Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder. Journal of child and adolescent psychopharmacology, 30(3), 128–136. https://doi.org/10.1089/cap.2019.0117

Coghill, D. R., Caballero, B., Sorooshian, S., & Civil, R. (2014). A systematic review of the safety of lisdexamfetamine dimesylate. CNS drugs, 28(6), 497–511. https://doi.org/10.1007/s40263-014-0166-2

Connor, D. F., Fletcher, K. E., & Swanson, J. M. (1999). A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 38(12), 1551–1559. https://doi.org/10.1097/00004583-199912000-00017

Cooper, R. E., Williams, E., Seegobin, S., Tye, C., Kuntsi, J., & Asherson, P. (2017). Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 27(8), 795–808. https://doi.org/10.1016/j.euroneuro.2017.05.005

Cortese, S., Adamo, N., Del Giovane, C., Mohr-Jensen, C., Hayes, A. J., Carucci, S., Atkinson, L. Z., Tessari, L., Banaschewski, T., Coghill, D., Hollis, C., Simonoff, E., Zuddas, A., Barbui, C., Purgato, M., Steinhausen, H. C., Shokraneh, F., Xia, J., & Cipriani, A. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The lancet. Psychiatry, 5(9), 727–738. https://doi.org/10.1016/S2215-0366(18)30269-4

Coughlin, C. G., Cohen, S. C., Mulqueen, J. M., Ferracioli-Oda, E., Stuckelman, Z. D., & Bloch, M. H. (2015). Meta-Analysis: Reduced Risk of Anxiety with Psychostimulant Treatment in Children with Attention-Deficit/Hyperactivity Disorder. Journal of child and adolescent psychopharmacology, 25(8), 611–617. https://doi.org/10.1089/cap.2015.0075

Daley, D., van der Oord, S., Ferrin, M., Danckaerts, M., Doepfner, M., Cortese, S., Sonuga-Barke, E. J., & European ADHD Guidelines Group (2014). Behavioral interventions in attention-deficit/hyperactivity disorder: a meta-analysis of randomized controlled trials across multiple outcome domains. Journal of the American Academy of Child and Adolescent Psychiatry, 53(8), 835–847.e8475. https://doi.org/10.1016/j.jaac.2014.05.013

Daviss, W. B., Patel, N. C., Robb, A. S., McDERMOTT, M. P., Bukstein, O. G., Pelham, W. E., Jr, Palumbo, D., Harris, P., Sallee, F. R., & CAT STUDY TEAM (2008). Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. Journal of the American Academy of Child and Adolescent Psychiatry, 47(2), 189–198. https://doi.org/10.1097/chi.0b013e31815d9ae4

Dijk, C. van, Zuidgeest, M., Dijk, L. van, & Verheij, R. (2008). Huisartsenzorg in cijfers: stijging behandeling ADHD bij kinderen. Huisarts en Wetenschap, 51, 641.

DosReis, S., Mychailyszyn, M. P., Evans-Lacko, S. E., Beltran, A., Riley, A. W., & Myers, M. A. (2009). The meaning of attention-deficit/hyperactivity disorder medication and parents’ initiation and continuity of treatment for their child. Journal of child and adolescent psychopharmacology, 19(4), 377–383. https://doi.org/10.1089/cap.2008.0118

EMEA-CHMP. (2009). Elements recommended for inclusion in summaries of product characteristics for methylphenidate-containing medicinal products authorised for the treatment of ADHD in children aged six years and above and adolescents. http://www.emea.europa.eu/pdfs/human/referral/methylphenidate/4461609en.pdf

Ermer, J. C., Pennick, M., & Frick, G. (2016). Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy. Clinical drug investigation, 36(5), 341–356. https://doi.org/10.1007/s40261-015-0354-y

Faber, A., van Agthoven, M., Kalverdijk, L. J., Tobi, H., de Jong-van den Berg, L. T., Annemans, L., & Postma, M. J. (2008). Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands. CNS drugs, 22(2), 157–170. https://doi.org/10.2165/00023210-200822020-00006

Faraone, S. V., Biederman, J., Spencer, T. J., & Aleardi, M. (2006). Comparing the efficacy of medications for ADHD using meta-analysis. MedGenMed: Medscape general medicine, 8(4), 4.

Faraone, S. V., Rostain, A. L., Montano, C. B., Mason, O., Antshel, K. M., & Newcorn, J. H. (2020). Systematic Review: Nonmedical Use of Prescription Stimulants: Risk Factors, Outcomes, and Risk Reduction Strategies. Journal of the American Academy of Child and Adolescent Psychiatry, 59(1), 100–112. https://doi.org/10.1016/j.jaac.2019.06.012

Findling, R. L., Quinn, D., Hatch, S. J., Cameron, S. J., DeCory, H. H., & McDowell, M. (2006). Comparison of the clinical efficacy of twice-daily Ritalin and once-daily Equasym XL with placebo in children with Attention Deficit/Hyperactivity Disorder. European child & adolescent psychiatry, 15(8), 450–459. https://doi.org/10.1007/s00787-006-0565-0

Findling, R. L., Ginsberg, L. D., Jain, R., & Gao, J. (2009). Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study. Journal of child and adolescent psychopharmacology, 19(6), 649–662. https://doi.org/10.1089/cap.2008.0165

Findling, R. L., Childress, A. C., Cutler, A. J., Gasior, M., Hamdani, M., Ferreira-Cornwell, M. C., & Squires, L. (2011). Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 50(4), 395–405. https://doi.org/10.1016/j.jaac.2011.01.007

Findling, R. L., McBurnett, K., White, C., & Youcha, S. (2014). Guanfacine extended release adjunctive to a psychostimulant in the treatment of comorbid oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder. Journal of child and adolescent psychopharmacology, 24(5), 245–252. https://doi.org/10.1089/cap.2013.0103

Galanter, C. A., Carlson, G. A., Jensen, P. S., Greenhill, L. L., Davies, M., Li, W., Chuang, S. Z., Elliott, G. R., Arnold, L. E., March, J. S., Hechtman, L., Pelham, W. E., & Swanson, J. M. (2003). Response to methylphenidate in children with attention deficit hyperactivity disorder and manic symptoms in the multimodal treatment study of children with attention deficit hyperactivity disorder titration trial. Journal of child and adolescent psychopharmacology, 13(2), 123–136. https://doi.org/10.1089/104454603322163844

Geller, D., Donnelly, C., Lopez, F., Rubin, R., Newcorn, J., Sutton, V., Bakken, R., Paczkowski, M., Kelsey, D., & Sumner, C. (2007). Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 46(9), 1119–1127. https://doi.org/10.1097/chi.0b013e3180ca8385

GGZ Standaard autisme,https://www.ggzstandaarden.nl/zorgstandaarden/autisme/behandeling-en-begeleiding

GGZ Standaard ADHD, https://www.ggzstandaarden.nl/zorgstandaarden/adhd/behandeling-en-begeleiding/medicamenteuze-behandeling

Gleason, M. M., Egger, H. L., Emslie, G. J., Greenhill, L. L., Kowatch, R. A., Lieberman, A. F., Luby, J. L., Owens, J., Scahill, L. D., Scheeringa, M. S., Stafford, B., Wise, B., & Zeanah, C. H. (2007). Psychopharmacological treatment for very young children: contexts and guidelines. Journal of the American Academy of Child and Adolescent Psychiatry, 46(12), 1532–1572. https://doi.org/10.1097/chi.0b013e3181570d9e

Goode, A. P., Coeytaux, R. R., Maslow, G. R., Davis, N., Hill, S., Namdari, B., LaPointe, N., Befus, D., Lallinger, K. R., Bowen, S. E., Kosinski, A., McBroom, A. J., Sanders, G. D., & Kemper, A. R. (2018). Nonpharmacologic Treatments for Attention-Deficit/Hyperactivity Disorder: A Systematic Review. Pediatrics, 141(6), e20180094. https://doi.org/10.1542/peds.2018-0094

Graham, J., Banaschewski, T., Buitelaar, J., Coghill, D., Danckaerts, M., Dittmann, R. W., Döpfner, M., Hamilton, R., Hollis, C., Holtmann, M., Hulpke-Wette, M., Lecendreux, M., Rosenthal, E., Rothenberger, A., Santosh, P., Sergeant, J., Simonoff, E., Sonuga-Barke, E., Wong, I. C., Zuddas, A., … European Guidelines Group (2011). European guidelines on managing adverse effects of medication for ADHD. European child & adolescent psychiatry, 20(1), 17–37. https://doi.org/10.1007/s00787-010-0140-6

Greenhill, L., Kollins, S., Abikoff, H., McCracken, J., Riddle, M., Swanson, J., McGough, J., Wigal, S., Wigal, T., Vitiello, B., Skrobala, A., Posner, K., Ghuman, J., Cunningham, C., Davies, M., Chuang, S., & Cooper, T. (2006). Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 45(11), 1284–1293. https://doi.org/10.1097/01.chi.0000235077.32661.61

Groenman, A. P., Oosterlaan, J., Rommelse, N. N., Franke, B., Greven, C. U., Hoekstra, P. J., Hartman, C. A., Luman, M., Roeyers, H., Oades, R. D., Sergeant, J. A., Buitelaar, J. K., & Faraone, S. V. (2013). Stimulant treatment for attention-deficit hyperactivity disorder and risk of developing substance use disorder. The British journal of psychiatry : the journal of mental science, 203(2), 112–119. https://doi.org/10.1192/bjp.bp.112.124784

 Groenman, A. P., Schweren, L. J., Dietrich, A., & Hoekstra, P. J. (2017). An update on the safety of psychostimulants for the treatment of attention-deficit/hyperactivity disorder. Expert opinion on drug safety, 16(4), 455–464. https://doi.org/10.1080/14740338.2017.1301928

Groenman, A. P., Schweren, L., Weeda, W., Luman, M., Noordermeer, S., Heslenfeld, D. J., Franke, B., Faraone, S. V., Rommelse, N., Hartman, C. A., Hoekstra, P. J., Buitelaar, J., & Oosterlaan, J. (2019). Stimulant treatment profiles predicting co-occurring substance use disorders in individuals with attention-deficit/hyperactivity disorder. European child & adolescent psychiatry, 28(9), 1213–1222. https://doi.org/10.1007/s00787-019-01283-y

Gucuyener, K., Erdemoglu, A. K., Senol, S., Serdaroglu, A., Soysal, S., & Kockar, A. I. (2003). Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities. Journal of child neurology, 18(2), 109–112. https://doi.org/10.1177/08830738030180020601

Hadland, S. E., Knight, J. R., & Harris, S. K. (2015). Medical marijuana: review of the science and implications for developmental-behavioral pediatric practice. Journal of developmental and behavioral pediatrics : JDBP, 36(2), 115–123. https://doi.org/10.1097/DBP.0000000000000129

Handen, B. L., Breaux, A. M., Gosling, A., Ploof, D. L., & Feldman, H. (1990). Efficacy of methylphenidate among mentally retarded children with attention deficit hyperactivity disorder. Pediatrics, 86(6), 922–930.

Handen, B. L., Feldman, H., Gosling, A., Breaux, A. M., & McAuliffe, S. (1991). Adverse side effects of methylphenidate among mentally retarded children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 30, 241-245.

Handen, B. L., Aman, M. G., Arnold, L. E., Hyman, S. L., Tumuluru, R. V., Lecavalier, L., Corbett-Dick, P., Pan, X., Hollway, J. A., Buchan-Page, K. A., Silverman, L. B., Brown, N. V., Rice, R. R., Jr, Hellings, J., Mruzek, D. W., McAuliffe-Bellin, S., Hurt, E. A., Ryan, M. M., Levato, L., & Smith, T. (2015). Atomoxetine, Parent Training, and Their Combination in Children With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 54(11), 905–915. https://doi.org/10.1016/j.jaac.2015.08.013

Hazell, P. L., & Stuart, J. E. (2003). A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. Journal of the American Academy of Child and Adolescent Psychiatry, 42(8), 886–894. https://doi.org/10.1097/01.CHI.0000046908.27264.00

Hechtman, L., & Greenfield, B. (2003). Long-term use of stimulants in children with attention deficit hyperactivity disorder: safety, efficacy, and long-term outcome. Paediatric drugs, 5(12), 787–794. https://doi.org/10.2165/00148581-200305120-00002

Hervas, A., Huss, M., Johnson, M., McNicholas, F., van Stralen, J., Sreckovic, S., Lyne, A., Bloomfield, R., Sikirica, V., & Robertson, B. (2014). Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 24(12), 1861–1872. https://doi.org/10.1016/j.euroneuro.2014.09.014

Hirota, T., Schwartz, S., & Correll, C. U. (2014). Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. Journal of the American Academy of Child and Adolescent Psychiatry, 53(2), 153–173. https://doi.org/10.1016/j.jaac.2013.11.009

Hoffman, K.S. (2018). CBD oil for ADHD? What the Research Says. https://chadd.org/attention-article/cbd-oil-for-adhd/

Humphreys KL, Eng T, Lee SS (2013). Stimulant medication and substance use outcomes: a metaanalysis. JAMA Psychiatry, 70(7):740-9.

Huss, M., Dirks, B., Gu, J., Robertson, B., Newcorn, J. H., & Ramos-Quiroga, J. A. (2018). Long-term safety and efficacy of guanfacine extended release in children and adolescents with ADHD. European child & adolescent psychiatry, 27(10), 1283–1294. https://doi.org/10.1007/s00787-018-1113-4

Huss, M., McBurnett, K., Cutler, A. J., Hervás, A., Bliss, C., Gao, J., Dirks, B., & Newcorn, J. H. (2019). Distinguishing the efficacy and sedative effects of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 29(3), 432–443. https://doi.org/10.1016/j.euroneuro.2018.05.012

Huss, M., Sikirica, V., Hervas, A., Newcorn, J. H., Harpin, V., & Robertson, B. (2016). Guanfacine extended release for children and adolescents with attention-deficit/hyperactivity disorder: efficacy following prior methylphenidate treatment. Neuropsychiatric disease and treatment, 112, 1085–1101. https://doi.org/10.2147/NDT.S94158

Huss, M., Chen, W., & Ludolph, A. G. (2016). Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe. Clinical drug investigation, 36(1), 1–25. https://doi.org/10.1007/s40261-015-0336-0

Jadad, A. R., Booker, L., Gauld, M., Kakuma, R., Boyle, M., Cunningham, C. E., et al. (1999a). The treatment of attention-deficit hyperactivity disorder: an annotated bibliography and critical appraisal of published systematic reviews and meta analyses. Canadian Journal of Psychiatry, 44, 1025-1035.

Jadad, A.R., Boyle, M., Cunningham, C., Kim, M., & Schachar, R. (1999b). Treatment of AttentionDeficit/Hyperactivity Disorder. Agency for Healthcare Research and Quality.

Jain, R., Segal, S., Kollins, S. H., & Khayrallah, M. (2011). Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 50(2), 171–179. https://doi.org/10.1016/j.jaac.2010.11.005

Jensen, P. S., Hinshaw, S. P., Swanson, J. M., Greenhill, L. L., Conners, C. K., Arnold, L. E., Abikoff, H. B., Elliott, G., Hechtman, L., Hoza, B., March, J. S., Newcorn, J. H., Severe, J. B., Vitiello, B., Wells, K., & Wigal, T. (2001). Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers. Journal of developmental and behavioral pediatrics: JDBP, 22(1), 60–73. https://doi.org/10.1097/00004703-200102000-00008

Jensen, P. S., Hinshaw, S. P., Kraemer, H. C., Lenora, N., Newcorn, J. H., Abikoff, H. B., March, J. S., Arnold, L. E., Cantwell, D. P., Conners, C. K., Elliott, G. R., Greenhill, L. L., Hechtman, L., Hoza, B., Pelham, W. E., Severe, J. B., Swanson, J. M., Wells, K. C., Wigal, T., & Vitiello, B. (2001). ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. Journal of the American Academy of Child and Adolescent Psychiatry, 40(2), 147–158. https://doi.org/10.1097/00004583-200102000-00009

Joseph, A., Ayyagari, R., Xie, M., Cai, S., Xie, J., Huss, M., & Sikirica, V. (2017). Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison. European child & adolescent psychiatry, 26(8), 875–897. https://doi.org/10.1007/s00787-017-0962-6

Kent, M. A., Camfield, C. S., & Camfield, P. R. (1999). Double-blind methylphenidate trials: practical, useful, and highly endorsed by families. Archives of pediatrics & adolescent medicine, 153(12), 1292–1296. https://doi.org/10.1001/archpedi.153.12.1292

Kollins, S. H., Jain, R., Brams, M., Segal, S., Findling, R. L., Wigal, S. B., & Khayrallah, M. (2011). Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics, 127(6), e1406–e1413. https://doi.org/10.1542/peds.2010-1260

Kooij, J., Bijlenga, D., Salerno, L., Jaeschke, R., Bitter, I., Balázs, J., Thome, J., Dom, G., Kasper, S., Nunes Filipe, C., Stes, S., Mohr, P., Leppämäki, S., Casas, M., Bobes, J., Mccarthy, J. M., Richarte, V., Kjems Philipsen, A., Pehlivanidis, A., Niemela, A., … Asherson, P. (2019). Updated European Consensus Statement on diagnosis and treatment of adult ADHD. European psychiatry, 56, 14–34. https://doi.org/10.1016/j.eurpsy.2018.11.001

Koster, E. S., de Haan, L., Bouvy, M. L., & Heerdink, E. R. (2015). Nonmedical Use of Attention-Deficit/Hyperactivity Disorder Medication Among Secondary School Students in The Netherlands. Journal of child and adolescent psychopharmacology, 25(8), 649–652. https://doi.org/10.1089/cap.2015.0099

Kratochvil, C. J., Wilens, T. E., Greenhill, L. L., Gao, H., Baker, K. D., Feldman, P. D., & Gelowitz, D. L. (2006). Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 45(8), 919–927. https://doi.org/10.1097/01.chi.0000222788.34229.68

Krinzinger, H., Hall, C. L., Groom, M. J., Ansari, M. T., Banaschewski, T., Buitelaar, J. K., Carucci, S., Coghill, D., Danckaerts, M., Dittmann, R. W., Falissard, B., Garas, P., Inglis, S. K., Kovshoff, H., Kochhar, P., McCarthy, S., Nagy, P., Neubert, A., Roberts, S., Sayal, K., … ADDUCE Consortium (2019). Neurological and psychiatric adverse effects of long-term methylphenidate treatment in ADHD: A map of the current evidence. Neuroscience and biobehavioral reviews, 107, 945–968. https://doi.org/10.1016/j.neubiorev.2019.09.023

Law, S. F., & Schachar, R. J. (1999). Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder?. Journal of the American Academy of Child and Adolescent Psychiatry, 38(8), 944–951. https://doi.org/10.1097/00004583-199908000-00009

Lee, S. S., Humphreys, K. L., Flory, K., Liu, R., & Glass, K. (2011). Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review. Clinical psychology review, 31(3), 328–341. https://doi.org/10.1016/j.cpr.2011.01.006

Leiblum, D.M. & van den Bergh, M. (2016). Moclobemide bij ADHD. Psyfar, 4(4).

Luan, R., Mu, Z., Yue, F., & He, S. (2017). Efficacy and Tolerability of Different Interventions in Children and Adolescents with Attention Deficit Hyperactivity Disorder. Frontiers in psychiatry, 8, 229. https://doi.org/10.3389/fpsyt.2017.00229

Loo-Neus, van de, G. H. H., Rommelse, N., & Buitelaar, J. K. (2011). To stop or not to stop? How long should medication treatment of Attention-Deficit Hyperactivity Disorder be extended? European Neuropsychopharmacology, 21(8), 584-599. https://doi.org/10.1016/j.euroneuro.2011.03.008

Martinez-Raga, J., Knecht, C., Szerman, N., et al. (2012). Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder. CNS Drugs, 27:15-30.

Matthijssen, A. M., Dietrich, A., Bierens, M., Kleine Deters, R., van de Loo-Neus, G., van den Hoofdakker, B. J., Buitelaar, J. K., & Hoekstra, P. J. (2019). Continued Benefits of Methylphenidate in ADHD After 2 Years in Clinical Practice: A Randomized Placebo-Controlled Discontinuation Study. The American journal of psychiatry, 176(9), 754–762. https://doi.org/10.1176/appi.ajp.2019.18111296

Matthijssen, A. M., Dietrich, A., Bierens, M., Kleine Deters, R., van de Loo-Neus, G., van den Hoofdakker, B. J., Buitelaar, J. K., & Hoekstra, P. J. (2020). Effects of Discontinuing Methylphenidate on Strengths and Difficulties, Quality of Life and Parenting Stress. Journal of child and adolescent psychopharmacology, 30(3), 159–165. https://doi.org/10.1089/cap.2019.0147

Mayes, S. D., Crites, D. L., Bixler, E. O., Humphrey, F. J., 2nd, & Mattison, R. E. (1994). Methylphenidate and ADHD: influence of age, IQ and neurodevelopmental status. Developmental medicine and child neurology, 36(12), 1099–1107. https://doi.org/10.1111/j.1469-8749.1994.tb11811.x

McCabe, S. E., Dickinson, K., West, B. T., & Wilens, T. E. (2016). Age of Onset, Duration, and Type of Medication Therapy for Attention-Deficit/Hyperactivity Disorder and Substance Use During Adolescence: A Multi-Cohort National Study. Journal of the American Academy of Child and Adolescent Psychiatry, 55(6), 479–486. https://doi.org/10.1016/j.jaac.2016.03.011

Meyers, J., Gajria, K., Candrilli, S. D., Fridman, M., & Sikirica, V. (2017). The impact of adjunctive guanfacine extended release on stimulant adherence in children/adolescents with attention-deficit/hyperactivity disorder. Journal of comparative effectiveness research, 6(2), 109–125. https://doi.org/10.2217/cer-2016-0039

Michelson, D., Buitelaar, J. K., Danckaerts, M., Gillberg, C., Spencer, T. J., Zuddas, A., Faries, D. E., Zhang, S., & Biederman, J. (2004). Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. Journal of the American Academy of Child and Adolescent Psychiatry, 43(7), 896–904. https://doi.org/10.1097/01.chi.0000125089.35109.81

Molina, B. S., Hinshaw, S. P., Eugene Arnold, L., Swanson, J. M., Pelham, W. E., Hechtman, L., Hoza, B., Epstein, J. N., Wigal, T., Abikoff, H. B., Greenhill, L. L., Jensen, P. S., Wells, K. C., Vitiello, B., Gibbons, R. D., Howard, A., Houck, P. R., Hur, K., Lu, B., Marcus, S., … MTA Cooperative Group (2013). Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. Journal of the American Academy of Child and Adolescent Psychiatry, 52(3), 250–263. https://doi.org/10.1016/j.jaac.2012.12.014

Molina, B., Hinshaw, S. P., Swanson, J. M., Arnold, L. E., Vitiello, B., Jensen, P. S., Epstein, J. N., Hoza, B., Hechtman, L., Abikoff, H. B., Elliott, G. R., Greenhill, L. L., Newcorn, J. H., Wells, K. C., Wigal, T., Gibbons, R. D., Hur, K., Houck, P. R., & MTA Cooperative Group (2009). The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. Journal of the American Academy of Child and Adolescent Psychiatry, 48(5), 484–500. https://doi.org/10.1097/CHI.0b013e31819c23d0

National Institute of Mental Health (2004a). Multimodal Treatment Study of ADHD follow-up: 24month outcomes of treatment strategies for Attention-Deficit/Hyperactivity Disorder. Pediatrics, 113(4), 754-761. https://doi.org/10.1542/peds.113.4.754

National Institute of Mental Health (2004b). Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics; 113(4), 762-769. https://doi.org/10.1542/peds.113.4.762

Newcorn, J.H, Kratochvil, C. J., Allen, A. J., Casat, C. D., Ruff, D. D., Moore, R. J., Michelson, D., & Atomoxetine/Methylphenidate Comparative Study Group (2008). Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. The American journal of psychiatry, 165(6), 721–730. https://doi.org/10.1176/appi.ajp.2007.05091676

Newcorn, J.H., Harpin, V., Huss, M., Lyne, A., Sikirica, V., Johnson, M., Ramos-Quiroga, J. A., van Stralen, J., Dutray, B., Sreckovic, S., Bloomfield, R., & Robertson, B. (2016). Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study. Journal of child psychology and psychiatry, and allied disciplines, 57(6), 717–728. https://doi.org/10.1111/jcpp.12492

Nieweg, E. H., & Batstra, L. (2012). Medicamenteuze behandeling van ADHD bij kinderen en adolescenten. Geneesmiddelenbulletin, 46, 121-129.

Ng Q. X. (2017). A Systematic Review of the Use of Bupropion for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Journal of child and adolescent psychopharmacology, 27(2), 112–116. https://doi.org/10.1089/cap.2016.0124

Osland, S. T., Steeves, T. D., & Pringsheim, T. (2018). Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. The Cochrane database of systematic reviews, 6(6), CD007990. https://doi.org/10.1002/14651858.CD007990.pub3

Ozbaran, B., Kose, S., Yuzuguldu, O., Atar, B., & Aydin, C. (2015). Combined methylphenidate and atomoxetine pharmacotherapy in attention deficit hyperactivity disorder. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 16(8), 619–624. https://doi.org/10.3109/15622975.2015.1051109

Padilha, S., Virtuoso, S., Tonin, F. S., Borba, H., & Pontarolo, R. (2018). Efficacy and safety of drugs for attention deficit hyperactivity disorder in children and adolescents: a network meta-analysis. European child & adolescent psychiatry, 27(10), 1335–1345. https://doi.org/10.1007/s00787-018-1125-0

Palumbo, D. R., Sallee, F. R., Pelham, W. E., Jr, Bukstein, O. G., Daviss, W. B., McDERMOTT, M. P., & CAT STUDY TEAM (2008). Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. Journal of the American Academy of Child and Adolescent Psychiatry, 47(2), 180–188. https://doi.org/10.1097/chi.0b013e31815d9af7

Pearson, D. A., Santos, C. W., Roache, J. D., Casat, C. D., Loveland, K. A., Lachar, D., Lane, D. M., Faria, L. P., & Cleveland, L. A. (2003). Treatment effects of methylphenidate on behavioral adjustment in children with mental retardation and ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 42(2), 209–216. https://doi.org/10.1097/00004583-200302000-00015

Pliszka, S. R., Greenhill, L. L., Crismon, M. L., Sedillo, A., Carlson, C., Conners, C. K., McCracken, J. T., Swanson, J. M., Hughes, C. W., Llana, M. E., Lopez, M., & Toprac, M. G. (2000). The Texas Children’s Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention-Deficit/Hyperactivity Disorder. Part I. Attention-Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 39(7), 908–919. https://doi.org/10.1097/00004583-200007000-00021

Pliszka, S. R., McCracken, J. T., & Maas, J. W. (1996). Catecholamines in attention-deficit hyperactivity disorder: current perspectives. Journal of the American Academy of Child and Adolescent Psychiatry, 35(3), 264–272. https://doi.org/10.1097/00004583-199603000-00006

Prince, J. B., Wilens, T. E., Biederman, J., Spencer, T. J., Millstein, R., Polisner, D. A., & Bostic, J. Q. (2000). A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder. Journal of child and adolescent psychopharmacology, 10(3), 193–204. https://doi.org/10.1089/10445460050167304

Pringsheim, T., Doja, A., Gorman, D., McKinlay, D., Day, L., Billinghurst, L., Carroll, A., Dion, Y., Luscombe, S., Steeves, T., & Sandor, P. (2012). Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 57(3), 133–143. https://doi.org/10.1177/070674371205700302

Quinn, P. D., Chang, Z., Hur, K., Gibbons, R. D., Lahey, B. B., Rickert, M. E., Sjölander, A., Lichtenstein, P., Larsson, H., & D’Onofrio, B. M. (2017). ADHD Medication and Substance-Related Problems. The American journal of psychiatry, 174(9), 877–885. https://doi.org/10.1176/appi.ajp.2017.16060686

Riddle, M. A., Yershova, K., Lazzaretto, D., Paykina, N., Yenokyan, G., Greenhill, L., Abikoff, H., Vitiello, B., Wigal, T., McCracken, J. T., Kollins, S. H., Murray, D. W., Wigal, S., Kastelic, E., McGough, J. J., dosReis, S., Bauzó-Rosario, A., Stehli, A., & Posner, K. (2013). The Preschool Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS) 6-year follow-up. Journal of the American Academy of Child and Adolescent Psychiatry, 52(3), 264–278.e2. https://doi.org/10.1016/j.jaac.2012.12.007

Sallee, F. R., McGough, J., Wigal, T., Donahue, J., Lyne, A., Biederman, J., & SPD503 STUDY GROUP (2009). Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry, 48(2), 155–165. https://doi.org/10.1097/CHI.0b013e318191769e

Savill, N. C., Buitelaar, J. K., Anand, E., Day, K. A., Treuer, T., Upadhyaya, H. P., & Coghill, D. (2015). The efficacy of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of clinical research. CNS drugs, 29(2), 131–151. https://doi.org/10.1007/s40263-014-0224-9

Scahill, L., Chappell, P. B., Kim, Y. S., Schultz, R. T., Katsovich, L., Shepherd, E., Arnsten, A. F., Cohen, D. J., & Leckman, J. F. (2001). A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. The American journal of psychiatry, 158(7), 1067–1074. https://doi.org/10.1176/appi.ajp.158.7.1067

Scahill, L., McCracken, J. T., King, B. H., Rockhill, C., Shah, B., Politte, L., Sanders, R., Minjarez, M., Cowen, J., Mullett, J., Page, C., Ward, D., Deng, Y., Loo, S., Dziura, J., McDougle, C. J., & Research Units on Pediatric Psychopharmacology Autism Network (2015). Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder. The American journal of psychiatry, 172(12), 1197–1206. https://doi.org/10.1176/appi.ajp.2015.15010055

Schachar, R., Jadad, A. R., Gauld, M., Boyle, M., Booker, L., Snider, A., Kim, M., & Cunningham, C. (2002). Attention-deficit hyperactivity disorder: critical appraisal of extended treatment studies. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 47(4), 337–348. https://doi.org/10.1177/070674370204700404

Schachter, H. M., Pham, B., King, J., Langford, S., & Moher, D. (2001). How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ: Canadian Medical Association journal = journal de l’Association medicale canadienne, 165(11), 1475–1488.

Schrantee, A., Tamminga, H. G., Bouziane, C., Bottelier, M. A., Bron, E. E., Mutsaerts, H. J., Zwinderman, A. H., Groote, I. R., Rombouts, S. A., Lindauer, R. J., Klein, S., Niessen, W. J., Opmeer, B. C., Boer, F., Lucassen, P. J., Andersen, S. L., Geurts, H. M., & Reneman, L. (2016). Age-Dependent Effects of Methylphenidate on the Human Dopaminergic System in Young vs Adult Patients With Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial. JAMA psychiatry, 73(9), 955–962. https://doi.org/10.1001/jamapsychiatry.2016.1572

Schrantee, A., Bouziane, C., Bron, E. E., Klein, S., Bottelier, M. A., Kooij, J., Rombouts, S., & Reneman, L. (2018). Long-term effects of stimulant exposure on cerebral blood flow response to methylphenidate and behavior in attention-deficit hyperactivity disorder. Brain imaging and behavior, 12(2), 402–410. https://doi.org/10.1007/s11682-017-9707-x

Schwartz, S., & Correll, C. U. (2014). Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. Journal of the American Academy of Child and Adolescent Psychiatry, 53(2), 174–187. https://doi.org/10.1016/j.jaac.2013.11.005

Stichting Farmaceutische Kengetallen, https://www.sfk.nl/publicaties/PW/2019/sterkere-daling-aantal-jonge-gebruikers-methylfenidaat

Short, E. J., Manos, M. J., Findling, R. L., & Schubel, E. A. (2004). A prospective study of stimulant response in preschool children: insights from ROC analyses. Journal of the American Academy of Child and Adolescent Psychiatry, 43(3), 251–259. https://doi.org/10.1097/00004583-200403000-00005

Simonoff, E., Taylor, E., Baird, G., Bernard, S., Chadwick, O., Liang, H., Whitwell, S., Riemer, K., Sharma, K., Sharma, S. P., Wood, N., Kelly, J., Golaszewski, A., Kennedy, J., Rodney, L., West, N., Walwyn, R., & Jichi, F. (2013). Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability. Journal of child psychology and psychiatry, and allied disciplines, 54(5), 527–535. https://doi.org/10.1111/j.1469-7610.2012.02569.x

Simoons, M., Seldenrijk, A., Mulder, H., Birkenhäger, T., Groothedde-Kuyvenhoven, M., Kok, R., Kramers, C., Verbeeck, W., Westra, M., van Roon, E., Bakker, R., & Ruhé, H. (2018). Limited Evidence for Risk Factors for Proarrhythmia and Sudden Cardiac Death in Patients Using Antidepressants: Dutch Consensus on ECG Monitoring. Drug safety, 41(7), 655–664. https://doi.org/10.1007/s40264-018-0649-z

Sonuga-Barke, E. J., Brandeis, D., Cortese, S., Daley, D., Ferrin, M., Holtmann, M., Stevenson, J., Danckaerts, M., van der Oord, S., Döpfner, M., Dittmann, R. W., Simonoff, E., Zuddas, A., Banaschewski, T., Buitelaar, J., Coghill, D., Hollis, C., Konofal, E., Lecendreux, M., Wong, I. C., … European ADHD Guidelines Group (2013). Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. The American journal of psychiatry, 170(3), 275–289. https://doi.org/10.1176/appi.ajp.2012.12070991

Spencer, T., Biederman, J., Wilens, T., Steingard, R., & Geist, D. (1993). Nortriptyline treatment of children with attention-deficit hyperactivity disorder and tic disorder or Tourette’s syndrome. Journal of the American Academy of Child and Adolescent Psychiatry, 32(1), 205–210. https://doi.org/10.1097/00004583-199301000-00029

Spencer, T. J., Sallee, F. R., Gilbert, D. L., Dunn, D. W., McCracken, J. T., Coffey, B. J., Budman, C. L., Ricardi, R. K., Leonard, H. L., Allen, A. J., Milton, D. R., Feldman, P. D., Kelsey, D. K., Geller, D. A., Linder, S. L., Lewis, D. W., Winner, P. K., Kurlan, R. M., & Mintz, M. (2008). Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. Journal of attention disorders, 11(4), 470–481. https://doi.org/10.1177/1087054707306109

Steele, M., Weiss, M., Swanson, J., Wang, J., Prinzo, R. S., & Binder, C. E. (2006). A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique, 13(1), e50–e62.

The MTA Cooperative Group (1999). Multimodal Treatment Study of Children with ADHD. A 14month randomized clinical trial of treatment strategies for Attention-Deficit/Hyperactivity Disorder. Archives of General Psychiatry, 56(12), 1073-1086. https://doi.org/10.1001/archpsyc.56.12.1073

The Tourette’s Syndrome Study Group (2002). Treatment of ADHD in children with tics. Neurology, 58(4), 527-536.

U.S. Food & Drug Administration (2020). What You Need to Know (And What We’re Working to Find Out) About Products Containing Cannabis or Cannabis-derived Compounds, Including CBD. https://www.fda.gov/consumers/consumer-updates/what-you-need-know-and-what-were-working-find-out-about-products-containing-cannabis-or-cannabis

Varley, C. K., & Trupin, E. W. (1982). Double-blind administration of methylphenidate to mentally retarded children with attention deficit disorder; a preliminary study. American journal of mental deficiency, 86(6), 560–566.

Viktorin, A., Rydén, E., Thase, M. E., Chang, Z., Lundholm, C., D’Onofrio, B. M., Almqvist, C., Magnusson, P. K., Lichtenstein, P., Larsson, H., & Landén, M. (2017). The Risk of Treatment-Emergent Mania With Methylphenidate in Bipolar Disorder. The American journal of psychiatry, 174(4), 341–348. https://doi.org/10.1176/appi.ajp.2016.16040467

Vidaurre, J., Twanow, J.D.E., (2017). Attention deficit hyperactivity disorder and associated cognitive dysfunction in pediatric epilepsy. Seminars in Pediatric Neurology, 24(4), 282-291.

Wang, C., Li, K., Seo, D. C., & Gaylord, S. (2020). Use of complementary and alternative medicine in children with ADHD: Results from the 2012 and 2017 National Health Interview Survey. Complementary therapies in medicine, 49, 102352. https://doi.org/10.1016/j.ctim.2020.102352

Wang, Y., Zheng, Y., Du, Y., Song, D. H., Shin, Y. J., Cho, S. C., Kim, B. N., Ahn, D. H., Marquez-Caraveo, M. E., Gao, H., Williams, D. W., & Levine, L. R. (2007). Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. The Australian and New Zealand journal of psychiatry, 41(3), 222–230. https://doi.org/10.1080/00048670601057767

Wigal, T., Greenhill, L., Chuang, S., McGOUGH, J., Vitiello, B., Skrobala, A., Swanson, J., Wigal, S., Abikoff, H., Kollins, S., McCRACKEN, J., Riddle, M., Posner, K., Ghuman, J., Davies, M., Thorp, B., & Stehli, A. (2006). Safety and tolerability of methylphenidate in preschool children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 45(11), 1294–1303. https://doi.org/10.1097/01.chi.0000235082.63156.27

Wigal T, Abikoff HB, Greenhill LL, Jensen PS, Wells KC, Vitiello B, Gibbons RD, Howard A, Houck PR, Hur K, Lu B, Marcus S; MTA Cooperative Group. (2013). Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. J Am Acad Child Adolesc Psychiatry, 52(3):250-63.

Wilens, T. E., Adler, L. A., Adams, J., Sgambati, S., Rotrosen, J., Sawtelle, R., Utzinger, L., & Fusillo, S. (2008). Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. Journal of the American Academy of Child and Adolescent Psychiatry, 47(1), 21–31. https://doi.org/10.1097/chi.0b013e31815a56f1

Wilens, T. E., Bukstein, O., Brams, M., Cutler, A. J., Childress, A., Rugino, T., Lyne, A., Grannis, K., & Youcha, S. (2012). A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 51(1), 74–85.e2. https://doi.org/10.1016/j.jaac.2011.10.012

Wilens, T. E., Newcorn, J. H., Kratochvil, C. J., Gao, H., Thomason, C. K., Rogers, A. K., Feldman, P. D., & Levine, L. R. (2006). Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. The Journal of pediatrics, 149(1), 112–119. https://doi.org/10.1016/j.jpeds.2006.01.052

Wilens, T. E., Faraone, S. V., Biederman, J., & Gunawardene, S. (2003). Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics, 111(1), 179–185. https://doi.org/10.1542/peds.111.1.179

Wilens, T. E., Robertson, B., Sikirica, V., Harper, L., Young, J. L., Bloomfield, R., Lyne, A., Rynkowski, G., & Cutler, A. J. (2015). A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 54(11), 916–25.e2. https://doi.org/10.1016/j.jaac.2015.08.016

Yang, R. W., & Li, R. (2019). Complementary and alternative medicine in ADHD treatment: more soundly designed clinical trials needed. World journal of pediatrics: WJP, 15(5), 516–519. https://doi.org/10.1007/s12519-019-00227-5

Zorgstandaard ADHD 2019. https://www.ggzstandaarden.nl/zorgstandaarden/adhd/introductie

Pubmed search:

ADHD AND children AND long term

Quinn, P. D., Chang, Z., Hur, K., Gibbons, R. D., Lahey, B. B., Rickert, M. E., Sjölander, A., Lichtenstein, P., Larsson, H., & D’Onofrio, B. M. (2017). ADHD Medication and Substance-Related Problems. The American journal of psychiatry, 174(9), 877–885. https://doi.org/10.1176/appi.ajp.2017.16060686

Feuer, A. J., Thai, A., Demmer, R. T., & Vogiatzi, M. (2016). Association of Stimulant Medication Use With Bone Mass in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder. JAMA pediatrics, 170(12), e162804. https://doi.org/10.1001/jamapediatrics.2016.2804

Osland, S. T., Steeves, T. D., & Pringsheim, T. (2018). Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. The Cochrane database of systematic reviews, 6(6), CD007990. https://doi.org/10.1002/14651858.CD007990.pub3

Martinez-Raga, J., Knecht, C., Szerman, N., & Martinez, M. I. (2013). Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder. CNS drugs, 27(1), 15–30. https://doi.org/10.1007/s40263-012-0019-9

Simoons, M., Seldenrijk, A., Mulder, H., Birkenhäger, T., Groothedde-Kuyvenhoven, M., Kok, R., Kramers, C., Verbeeck, W., Westra, M., van Roon, E., Bakker, R., & Ruhé, H. (2018). Limited Evidence for Risk Factors for Proarrhythmia and Sudden Cardiac Death in Patients Using Antidepressants: Dutch Consensus on ECG Monitoring. Drug safety, 41(7), 655–664. https://doi.org/10.1007/s40264-018-0649-z

Meyers, J., Gajria, K., Candrilli, S. D., Fridman, M., & Sikirica, V. (2017). The impact of adjunctive guanfacine extended release on stimulant adherence in children/adolescents with attention-deficit/hyperactivity disorder. Journal of comparative effectiveness research, 6(2), 109–125. https://doi.org/10.2217/cer-2016-0039

Findling, R. L., McBurnett, K., White, C., & Youcha, S. (2014). Guanfacine extended release adjunctive to a psychostimulant in the treatment of comorbid oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder. Journal of child and adolescent psychopharmacology, 24(5), 245–252. https://doi.org/10.1089/cap.2013.0103

Vidaurre, J., Twanow, J.D.E., (2017). Attention deficit hyperactivity disorder and associated cognitive dysfunction in pediatric epilepsy. Seminars in Pediatric Neurology, 24(4), 282-291.

 

Epilepsy children AND ADHD stimulants

Groenman, A. P., Schweren, L., Weeda, W., Luman, M., Noordermeer, S., Heslenfeld, D. J., Franke, B., Faraone, S. V., Rommelse, N., Hartman, C. A., Hoekstra, P. J., Buitelaar, J., & Oosterlaan, J. (2019). Stimulant treatment profiles predicting co-occurring substance use disorders in individuals with attention-deficit/hyperactivity disorder. European child & adolescent psychiatry, 28(9), 1213–1222. https://doi.org/10.1007/s00787-019-01283-y

Ahmed, R., Borst, J., Wei, Y. C., & Aslani, P. (2017). Parents’ Perspectives About Factors Influencing Adherence to Pharmacotherapy for ADHD. Journal of attention disorders, 21(2), 91–99. https://doi.org/10.1177/1087054713499231